The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast

European Journal of Cancer and Clinical Oncology

Volumn 24, Issue 10, 1988, Pages 1567-1572

  Howell, A ^a   Mackintosh, J ^a   Jones, Mary ^b   Redford, Judith ^c   Wagstaff, J ^a   Sellwood, R A ^c  

^a CRC Department of Medical Oncology   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c WITHINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MITOLACTOL; MITOMYCIN C; PREDNISOLONE; TAMOXIFEN; VINBLASTINE; VINCRISTINE;

BREAST CANCER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMAN; OVARIECTOMY; PROGNOSIS; TAMOXIFEN; TIME FACTORS;

EID: 0023708345     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-5379(88)90046-6     Document Type: Article

References (29)

1. Assessment of response to therapy in advanced breast cancer
2. Reporting results of cancer treatment
3. Toxicity and response criteria of the Eastern Cooperative Oncology Group
4. Analysis of survival by tumor response
5. Comparison of four-combination chemotherapy programs in metastatic breast cancer
6. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen
7. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer
8. An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer
9. Chemotherapy vs. chemoimmunotherapy with methanol extraction residue of bacillus calmette-guerin (MER) in advanced breast cancer
10. Aminoglutethimide in advanced breast cancer: cliical results of a French multicenter randomized trial comparing 500 mg and 1 g/day
11. Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer
12. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil adriamycin, cyclophosamide, and BCG
13. Low dose chemotherapy of metastatic breast cancer with cyclophosamide, adriamycin, methotextrate, 5-fluorouracil (CAMF) versus sequential cyclophosamide, methotextrate, 5-fluorouracil (CMF) and adriamycin
14. Doxorubicin mitolactol dibromodulcitol, and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosomide, methotextrate, 5-FU, vincristine and prednisolone (CMFP)
15. A phase II study of combined 5-fluorouracil and mitomycin C in advanced breast cancer
16. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma
17. Megestrol acetate therapy for advanced breast cancer
18. Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M.D. Anderson Hospital experience
19. Progestin therapy in advanced breast cancer: megestrol acetate—an evaluation of 160 treated cases
20. Criteria of tumor response used in clinical trials of chemotherapy
21. Cyclical combination chemotherapy for advanced breast carcinoma
22. Combination therapy with adriamycin and cyclophosamide for advanced breast cancer
23. VAP-Cyclo—a short intensive regimen of chemotherapy for advanced breast cancer
24. Dibromodulcitol, mitomycin C and vinblastine (DMV) chemotherapy in advanced breast cancer
25. Nonparametric estimation from incomplete observations
26. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples
27. On a test of whether one of two random variables is stochastically larger than the other
28. Progesterone receptor measurement by isoelectric focussing: a potential micro-assay
29. Isoelectric focussing of oestradiol receptor protein from human mammary carcinoma—a comparison with dextran coated charcoal assay